Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614885 | 0.85 | KMT2A (0.33) | KMT2AALDH1A1TNFMMP2MMP9 | |
| SCHEMBL236129 | 0.80 | ADRB1 (0.32) | — | |
| SCHEMBL234138 | 0.80 | ADRB1 (0.32) | — | |
| SCHEMBL613334 | 0.78 | KMT2A (0.38) | KMT2AALDH1A1MAPK1MEN1THRB | |
| SCHEMBL2209288 | 0.74 | ADRB1 (0.48) | KMT2AALDH1A1DRD3MAPK1MEN1 | |
| SCHEMBL17024423 | 0.74 | ADRB1 (0.48) | KMT2AALDH1A1DRD3MAPK1MEN1 | |
| SCHEMBL232836 | 0.74 | POLB (0.31) | POLB | |
| SCHEMBL611891 | 0.74 | HPGD (0.38) | KMT2AALDH1A1MMP2MMP9MAPK1 | |
| SCHEMBL15461598 | 0.72 | RIPK1 (0.36) | KMT2AALDH1A1DRD3MAPK1MEN1 | |
| SCHEMBL237579 | 0.71 | PNMT (0.43) | KMT2AMAPK1MEN1THRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | KMT2A 1037/4885ALDH1A1 641/4885TNF 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.